The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose level tracking, giving users actionable insights. The company has been concentrating on product development ...